DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

11.42 0.12 (1.06%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

BCRX $11.42 1.06%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $11.29
Previous Close $11.30
Daily Range $11.15 - $11.50
52-Week Range $7.85 - $14.62
Market Cap $828.2M
P/E Ratio -15.69
Dividend (Yield) $0.00 (0.0%)
Volume 438,360
Average Daily Volume 693,212
Current FY EPS -$1.03

Sector

Healthcare

Industry

Drug Makers

BioCryst Pharmaceuticals, Inc. (BCRX) Description

A biotechnology company, which designs, optimizes and develops novel drugs that block key enzymes involved in cancer, cardiovascular diseases, autoimmune diseases, and viral infections. Website: http://www.biocryst.com/

News & Commentary Rss Feed

Why BioCryst Pharmaceuticals, Inc. Shares Scorched Higher

BioCryst shares launch higher for a second straight day following a substantial contract win from the U.S. government.

Insider Trading Alert - BDN, MRCY And BCRX Traded By Insiders

US Stock Futures Rise Ahead Of Economic Data

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX7353 for the Treatment of Hereditary Angioedema

Oppenheimer Reviews BioCryst Earnings

BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q1 2015 Results - Earnings Call Transcript

BioCryst Pharmaceuticals (BCRX) Q1 2015 Results - Earnings Call Webcast

These 10 Stocks Could Move Big On Monday

Benzinga's Top Initiations

FBR Capital Initiates Biocryst Pharmaceuticals With Outperform

BioCryst Upgrade Almost Looks Misunderstood

See More BCRX News...

BCRX's Top Competitors

BCRX $11.42 (1.06%)
Current stock: BCRX
GILD $111.71 (0.44%)
Current stock: GILD
CELG $116.09 (-0.09%)
Current stock: CELG
BIIB $398.68 (-0.62%)
Current stock: BIIB